Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 2, 1996, Pages 117-122

  Heinonen, Therese M ^a   Schrott, Helmut ^b   McKenney, James M ^c   Sniderman, Allan D ^d   Broyles, Frances E ^e   Zavoral, James H ^f   Kivel, Frances ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e Pacific Biometrics Inc   (United States)

^f Preventive Cardiology Institute   (United States)

Author keywords

Atorvastatin; Colestipol; Compliance; Efficacy; Hypercholesterolemia; Safety

Indexed keywords

EID: 0000111806     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100205     Document Type: Article

References (12)

1. Lipid Research Clinics Program. The lipid research clinics primary prevention trial results I and II. JAMA 251:351, 1984.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin survival study (4s). Lancet 344:1383, 1994.
3. Expert Panel on Detection, Evaluation. and Treatment of High Blood Cholcstcrol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Wxpert panel on Detectin, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269:3015, 1993.
4. Illingworth DR. New horizons in combination drug therapy for hypercholesterolemia. Cardiology 76(Suppl 1):83, 1989.
5. Illingworth DR, Gowan D. Management of lipoprotein abnormalities. Recent Adv Cardiol 10:71, 1987.
6. lllingworth DR. Lipid lowering drugs: An overview of indications and optimum therapeutic use. Drugs 33:259, 1987.
7. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolernia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678, 1995.
8. Remmell PS, Benfari RC. Assessing dietary adherence in the multiple risk factor intervention trial (MRFIT)II: Food record rating as an indicator or compliance. J Am Diet Assoc 76:357, 1980.
9. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma. without the use of the preparative ultracentrifuge. Clin Chem 18:499, 1972.
10. Warnick GR, Benderson J, Albers JJ,et al.Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379, 1982.
11. Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern bled 101:598, 1984.
12. Erkelens DW. Combination drug therapy with HMG-CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 77(Suppl 4):33, 1990.